Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer
Conclusions:
This study revealed a key pathway that contributes to anthracycline resistance and established model systems for investigating drug resistance in all four major breast cancer subtypes. As the histone modification can be targeted with small-molecule inhibitors, it represents a possible means of reversing clinical anthracycline resistance.Trial registrationClinicalTrials.gov identifier NCT00003012. Registered on 1 November 1999.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Marsela BraunsteinLinda LiaoNicola LyttleNazleen LoboKaren TaylorPaul KrzyzanowskiIrina KalatskayaCindy YaoLincoln SteinPaul BoutrosChristopher TwelvesRichard MarcellusJohn BartlettMelanie Spears Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Genetics | Multidrug Resistance | Study